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ABSTRACT                                                                                                              
 
BACKGROUND:  Drug use evaluation is a performance improvement method that focuses on evaluation and 
improvement of drug use processes to achieve optimal patient outcomes. The objective of this study was to evaluate 
the use of cotrimoxazole for prophylaxis among people living with HIV/AIDS in Jimma University Specialized 
Hospital.  
METHODS: Drug use evaluation criteria were set along with threshold based on the national guidelines for 
cotrimoxazole preventive therapy. The study was done by a cohort design with retrospective review of medical 
records of r sixty people with HIV/AIDS who have been on cotrimoxazole prophylaxis in the hospital from January 
19, 2006 to January 18, 2007. A systematic sampling method was used to select records of the study participants. 
Data were collected from January 19 to February 3, 2007 using structured format and evaluated against the set 
criteria and thresholds.  
RESULTS: Fifty one (85.0%) patients were in the age range of 15 to 49 years and 33 (55.0%) were females. In all 
cases, the indication to start, dose and frequency of administration of cotrimoxazole were according to the national 
guidelines for Cotrimoxazole Preventive Therapy. Forty-six (76.6%) cases were consistent with guidelines for 
indications to discontinue the drug; however, CD4 count was done only for 28 (46.7%) of patients during follow-up. 
Fifty-eight (96.7%) and 59(98.3%) of the cases were in accordance with the guidelines for contraindication and 
drug interactions, respectively. 
CONCLUSION:  The use of cotrimoxazole for preventive therapy for people living with HIV/AIDS was found to be 
good in Jimma University Specialized Hospital with regard to initiation and dosage. However, the practice of 
discontinuation of cotrimoxazole and follow-up for drug adverse effects should be improved by proper 
implementation of the guideline.  




One of the most pressing problems facing public health 
providers and administrators in many countries is 
ensuring rational drug use. The Conference of Experts on 
the Rational Use of Drugs, convened by the World 
Health Organization (WHO) in Nairobi in 1985, defined 
rational drug use as: “The rational use of drugs requires 
that patients receive medications appropriate to their 
clinical needs, in doses that meet their own individual 
requirements, for an adequate period of time, and at the 
lowest cost to them and their community”. Rational drug 
use implies an individual approach to patient treatment. 
The presence of standard treatment guidelines and drug 
formularies for selected drugs in a health facility does not 
ensure that they are prescribed and used correctly. One 
mechanism to ensure correct prescribing and use is drug 
use evaluation (DUE) (1). 
 DUE is a performance improvement method that 
focuses on evaluating and improving drug use processes 
to achieve optimal patient outcomes. DUE may be 
applied to a drug or therapeutic class, or diagnosis. 
Through its focus on the system of drug use, DUE helps 
to identify actual and potential drug-related problems, 
resolve actual drug-related problems, and prevent 
potential drug-related problems that could interfere with 
achieving optimum outcomes from drug therapy (23).  
 Antibiotics represent approximately 30% of acute 
care hospitals’ drug expenditure and they are prescribed 
for 20-50% of inpatients. The development of bacterial 
resistance to antibiotics has become a major problem 
throughout the world. Resistant organisms may emerge 
as a result of many factors, including irrational use of 
drugs. Studies have shown that 22-65% of antibiotic 
prescriptions are inappropriate. In several situations, the 
rational use of antibiotics has been reported to reduce the 
emergence of resistant strains (4-6). DUE is one of the 
increasingly used methods in combating the development 
of bacterial resistance to antimicrobial agents (5).  
 Pneumocystis carini pneumonia (PCP) is the most 
common AIDS-defining illness. Cotrimoxazole (CTX) 
prophylaxis was shown to effectively prevent PCP in 
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patients with clinical evidence of immune suppression 
(7-9). WHO and the Joint United Nations Program on 
HIV/AIDS (UNAIDS) have recommended CTX 
preventive therapy (CPT) for PLWHA in Africa with 
symptomatic HIV disease (WHO stage 2, 3 or 4) and 
asymptomatic individuals who have a CD4 count of less 
than or equal to 500 cells/mm
3
. Wide-scale use of 
prophylactic CTX may increase the spread of 
antimicrobial resistance in communities to other 
pathogens. It would therefore be prudent to confine the 
use of CPT only to those patients who will benefit from it 
(10).  
 Ethiopia has adopted the WHO recommendation 
and the first TB/HIV and antiretroviral guidelines were 
issued by Ministry of Health in 2005. So far, there are no 
published reports in the country aimed at evaluating 
whether the actual use of CTX for prophylaxis is inline 
with the guidelines or not. This study evaluated the use of 
CTX prophylaxis among people living with HIV/AIDS 
on follow-up at Jimma University Specialized Hospital.  
 
METHODS AND MATERIALS 
 
The study was conducted in Jimma University 
Specialized Hospital (JUSH) which is found in Jimma 
Town, South-West Ethiopia.   A total of 2155 PLWHA 
were registered for follow-up care in the hospital until 
January 19, 2007. Among these, 1293(60%) were taking 
CTX for preventive therapy. The Number of patients to 
be included in the study was determined based on DUE 
guideline recommendation that a DUE report should 
include data from 30 to 50 cases for commonly 
prescribed drugs (1). Accordingly, sixty records were 
selected using systematic sampling method from 
sequentially arranged medical records (by date of CTX 
initiation) of PLWHA that were on CPT in the hospital 
during the period of January 19, 2006 to January 18, 
2007. Medical records of patients who have been on 
CTX for less than three months were excluded from the 
study since they have inadequate follow-up data for 
evaluation.  
 Drug use evaluation criteria with thresholds were 
set based on the 2005 national guidelines (11,12). The 
criteria included were; indications to start and 
discontinue CTX, dose and frequency of administration, 
contraindications, adverse drug reactions (ADR), and 
some laboratory tests conducted for monitoring patient 
conditions. For each criterion a threshold limit was set to 
measure the extent of practitioner’s adherence to the 
national CPT guidelines (Table 1).  
 One nurse working in the antiretroviral therapy 
(ART) clinic collected the data using a pre-tested data 
collection format. The collected data were analyzed using 
Excel spreadsheet and interpreted and the results were 
evaluated against the set criteria and thresholds, and 




Sixty patients’ records were evaluated for CPT 
appropriateness. Fifty one (85.0%) patients were in the 
age group of 15 to 49 years whereas 7 (11.7%) and 2 
(3.3%) were under 15 and above 50 years of age, 
respectively. Thirty-three (55.0%) patients were females 
and 31(51.7%) were in the age group of 15-49 years. One 
female was pregnant but the pregnancy history of 11 
(35.5%) females was not documented (Table 2).
    
 
Table 2. Age and sex distribution of PLWHA on CPT in JUSH, January 19, 2006 to January 18, 2007. 
 
 
                Variable     Number Percent 
Age       < 15 years 
              15-49 years 
              Above 50 years                
              Total 
Sex         Male 
               Female                           
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          Table 1. Drug use evaluation criteria for CPT for PLWHA  
 
Criteria Threshold (%) 
Indications to start 
Adults 
 HIV–positive patient with active TB 
 Symptomatic HIV disease (Stages 2, 3 or 4 of WHO 
HIV  clinical staging) 
 Asymptomatic patient, CD4 < 500cells/mm
3
 
Children > 15months  
 Have event of PCP  
 Have symptomatic infection  
 AIDS defining illness  
 CD4 Percent < 15% 
 Infants > 6 weeks 
Born to HIV positive mother 
100 
Indications to discontinue 
Adults 
 CD4>500cells/mm3   
 Severe anemia (Hgb<7g/dl) at least for 3 months 
 Severe thrombocytopenia (platelet < 50,000cells/ml) 
 Severe Neutropenia (Neutrophil <750cells/ml) 
 1st trimester of pregnancy 
Children 




   Adults:  
 960 mg/day 
    Children 
 < 6 months: 120 mg/day  
 6 months-5 years: 240 mg/day 
6-14 years: 480 mg/day 
100 
Contraindications 
 Sulfa allergy  
  First trimester of pregnancy Breast feeding 
mothers during the 1
st
 6 weeks 
 Renal insufficiency (Creatinine >1.5 mg/dl) 
 Hepatic diseases  (SGPT>115 UI/L for males, 90 
UI/L for females ) 
 Bone marrow suppression 
- Severe anemia (Hgb < 7g/dl) 
- Severe Neutropenia (Neutrophil < 750 
cells/mm
3 
)    
 
  










 CD4 count every 3 months 
 CBC every 3 months 
Creatinine every 3 months 
80 





















Figure 2: Laboratory tests for monitoring of CPT for PLWHA in JUSH, January 19, 2006 to January    18, 2007. 
 
 
Table 3: Actual performance versus set criteria and thresholds for CPT for PLWHA in JUSH, January 19, 2006 to 




Actual performance  
No. (%) 
Indication to star CTX 60 (100)  60 (100) 
Indication to discontinue CTX 60 (100) 45 ( 76.6) 
Dose 60 (100) 60 (100) 
Contraindication 54 (95) 58 (96.7) 
Drug Interactions 54 (95) 59 (98.3) 
Monitoring 48 (80) 28 (46.7) 
 
The average duration of CPT was 306.8 days (range 135-
729 days). Forty-five (75.0%) patients have been taking 
CTX for a duration of six months to one year.  CPT was 
started for majority of the patients 31(51.7%) while they 
were in WHO clinical disease stage 3 (Figure 1). All 
adults were taking 960 mg daily and children were taking 
depending on their age: 120 mg/day for under 6 months, 
240 mg/day for 6 months to 5 years and 480 mg/day for 
6-15 years of age.  
 CTX was discontinued in 17 (28.3%) patients of 
which the CD4 count was between 200 and 500 
cells/mm
3
 with a mean count of 339 cells/ mm
3
 in 11 
(64.7%) of them. Only two patients (12.5%) stopped CPT 
according to the guideline. One patient (5.9%) was put 
off CTX due to severe allergic reaction. The reason for 
discontinuation of CPT was not recorded in 3 (17.6%) of 
the patients.  
Two(3.3%) patients received CTX despite the presence 
of contraindication. A pregnant lady was taking CTX 
throughout her gestation. CTX was concurrently used 
with Zidovudine (ZDV) at the time of the study in 18 
cases. Hemoglobin was checked only for eleven of these 
concurrent users of CTX and ZDV. Severe anemia was 
documented in 1 (5.6%) case for whom ZDV was 
discontinued but CTX was not.  
 ADR was recorded in 4 (6.7%) patients which 
included persistent pruritic eruption 2(50.0%) and severe 
anemia and allergic reactions, 1(25.0%) each. Monitoring 
of patient conditions during initiation and use of CTX 
was based on laboratory tests. Initially, CD4 count, 
Complete Blood Count (CBC), Liver Function Test 
(LFT), Hgb   and Renal Function Test (RFT) were 
performed for 51(85.0%), 36(60.0%), 36 (60.0%), 35 
(58.3%) and 25(41.7%) of the patients, respectively. 
During follow-up, the same tests were performed for 
28(46.7%), 21(35%), 4(6.7%), 21(35%), and 3(5%) 
patients, respectively (Figure 2).    
 Only one of the 18 patients (5.6%) that were taking 
CTX with ZDV experienced severe anemia. In seven 
(38.9%) of the 18 patients the level of Hgb or CBC were 
not documented. Other drug interactions with CTX were 
not documented. Therefore, the threshold set for drug 
interaction with CTX (95.0%) was achieved though the 
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who were taking CTX and ZDV concurrently. Table 3 
summarizes the finding of this study in relation to the set 
criteria and thresholds. The thresholds set for most of 





























Practitioners fully adhered to the 2005 national CPT 
guideline with regard to indication to start CTX 
preventive therapy though there was a problem in 
discontinuing the drug. The national CPT guideline 
recommends discontinuation of CTX when the CD4 
count is greater than 500cells/mm
3
. Only two patients 
(12.5%) stopped CPT according to the guideline. Patients 
on CPT should be monitored appropriately in order to 
assess their progresses as a result of prophylaxis to look 
ADRs and initiate appropriate management. Monitoring 
of patients on CPT also enables practitioners to assess 
patients’ adherence to their medication and discontinue 
the drug when the CD4 count is restored to the 
recommended level. 
 All adults were taking 960mg of CTX daily which 
is consistent with the guideline(11, 12). Children were 
taking CTX daily on the basis of their age. For pediatrics, 
the guideline recommends to follow the WHO Guidelines 
on CTX Prophylaxis (9). Intermittent dosing of CTX was 
reported to be more acceptable to patients, reduces health 
service cost and the risk of neutropenia (13). 
Nevertheless, the 2006 national guideline recommends 
the daily use of CTX and the hospital practice was inline 
with it (14). Therefore, the threshold set for dose and 
frequency of use of CTX was achieved 100% for both 
adult and pediatric patients. 
 There were 3(5.0%) patients in which skin 
manifestations of ADR were documented in relation to 
CTX use. Two patients developed persistent pruritic 
eruption (PPE) which was managed by antihistamines 
and topical anti-inflammatory agents. In one case, the 
patient was said to be allergic to CTX but whether the 
patient was initially allergic to sulfa drugs or developed 
allergy for the first time on the course of therapy was not 
documented. 
  CTX was used despite contraindications in two 
cases; patient with hemoglobin 4.9g/dl and pregnant 
woman during the whole period of pregnancy. The first 
case was managed by changing the ZDV. Guidelines 
recommend monitoring of ZDV toxicity when ZDV and 
CTX are used concurrently (15). The CD4 count of the 
pregnant woman was 218/mm
3
, which was adequate to 
discontinue the drug according to the current practice in 
the hospital. The pregnancy history of one third of female 
patients who were in the fertile age group was not 
documented. This might imply that CXT may have been 
used in other pregnant women during the first trimester 
of pregnancy. 
 According to the national guidelines during follow-
up, routine laboratory tests are not required but 
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indications for CBC and RFT every three months. 
Inline with this, CBC and Hgb levels were determined 
for 21 (35.0%) patients at least once during their course 
of CPT. LFT and RFT were performed in 4(6.7%) and 
3(5.0%) patients, respectively. Even though the average 
stay of patients on CPT in this study was 306 days, the 
CD4 count and the CBC or Hgb level of all patients 
should have been measured at least once during the 
course of CPT for better care.  
 In this hospital, follow-up of pediatric patients was 
appropriately done and documented as compared to 
adults where only some laboratory tests were conducted 
to assess the development of certain ADRs and the level 
of CD4 count of the patients. CD4 count was performed in 
28 (46.7%) of the patients at least once during the course 
of CPT and this enabled to withdraw CPT in those 
patients with improved CD4 counts to the recommended 
level. This helps to reduce the pill burden of patients on 
ART thereby to improve their adherence and treatment 
outcome. 
 To date, there are no published studies conducted 
on evaluation of cotrimoxazole use for prophylaxis in 
PLWHA and hence it was not possible to compare the 
practice of this hospital with practices of other clinical 
settings. The findings were discussed in relation to the 
2005 CPT guideline of Ethiopia.  
In conclusion, the overall use of CTX in PLWHA in 
JUSH was inline with the national guidelines and met the 
thresholds set for most of the criteria. But, 
discontinuation of CPT for those patients showing 
improvements in their CD4 count was not according to 
the national guidelines. Moreover, monitoring for 
adverse reactions during follow-up visits was not 
consistently done for all patients. Therefore, the practice 
of discontinuation of cotrimoxazole and follow-up for 
adverse drug effects should be improved by proper 
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